Overview

Avelumab and M1774 in ARID1A-mutated Endometrial Cancer

Status:
RECRUITING
Trial end date:
2029-08-31
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to see if the combination of study drugs avelumab and M1774 is effective and safe for participants with endometrial cancer. The names of the study drugs involved in this study are: * Avelumab (a type of human IgG1 antibody) * M1774 (a type of ATR inhibitor)
Phase:
PHASE2
Details
Lead Sponsor:
Panagiotis Konstantinopoulos, MD, PhD
Collaborators:
EMD Serono
The Applebaum Foundation
Treatments:
avelumab